Onco360 Selected for BRAFTOVI ™ (encorafenib) and MEKTOVI® (binimetinib) Limited Distribution Pharmacy Network

"BRAFTOVI and MEKTOVI provide another important therapeutic option for patients with unresectable or metastatic melanoma with BRAF ^B600E or BRAF^V600K mutations,” said Onco360 President and CEO Paul Jardina. “The world’s top biopharmaceutical companies, including Array Biopharma, continue to leverage Onco360’s patient-centric approach to cancer care when choosing a pharmacy network to distribute their pioneering new treatments in oncology. We are pleased to have been selected to join the limited distribution network for BRAFTOVI and MEKTOVI and look forward to providing outstanding care to patients who have a critical need for this therapy.”

BRAFTOVI (encorafenib) and MEKTOVI (binimetinib) were approved by The U.S. Food and Drug Administration (FDA) on June 27, 2018 based on clinical data from the Phase 3 COLUMBUS study, published in the Lancet Oncology.¹ More information about these products can be found at www.braftovimektovi.com.

Metastatic melanoma is the most life-threatening type of skin cancer, associated with low survival rates. An estimated half of the 200,000 new cases of melanoma diagnosed worldwide each year have BRAF mutations, a key target in the treatment of metastatic melanoma.

About Onco360 Oncology Pharmacy:

Onco360 is the largest independent Oncology Pharmacy and clinical support services company in the country. Onco360 was founded in 2003 to bring together the stakeholders involved in the cancer treatment process and serve the specialized needs of oncologists, patients, hospitals, cancer centers of excellence, manufacturers, health plans, and payers. It dispenses nationally through its network of URAC, ACHC, and JCAHO-accredited Oncology Pharmacies. Onco360 is headquartered in Louisville, KY, and is a flagship specialty pharmacy brand of PharMerica Corporation, a leading institutional pharmacy, specialty infusion and hospital services company servicing healthcare facilities in the United States. For more information about Onco360 please visit www.Onco360.com.

[1] Ascierto PA, et al. Lancet Oncol. 2016;17:1248-1260

View source version on businesswire.com: https://www.businesswire.com/news/home/20180702005323/en/